| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 154 | 2026 | 3340 | 12.620 |
Why?
|
| Neoplasm Metastasis | 68 | 2026 | 1089 | 9.140 |
Why?
|
| Radiotherapy | 48 | 2025 | 325 | 8.330 |
Why?
|
| Immunotherapy | 41 | 2026 | 821 | 5.890 |
Why?
|
| Radiation Tolerance | 76 | 2026 | 179 | 5.110 |
Why?
|
| Genetic Therapy | 47 | 2015 | 373 | 4.870 |
Why?
|
| Tumor Necrosis Factor-alpha | 44 | 2017 | 707 | 4.690 |
Why?
|
| Radiosurgery | 25 | 2025 | 351 | 4.570 |
Why?
|
| Combined Modality Therapy | 156 | 2025 | 1750 | 4.390 |
Why?
|
| Head and Neck Neoplasms | 110 | 2018 | 1088 | 4.360 |
Why?
|
| Carcinoma, Squamous Cell | 103 | 2017 | 1105 | 3.870 |
Why?
|
| Animals | 302 | 2026 | 28910 | 3.500 |
Why?
|
| Radiation, Ionizing | 46 | 2024 | 123 | 3.500 |
Why?
|
| Mice | 205 | 2026 | 12707 | 3.480 |
Why?
|
| Radioimmunotherapy | 7 | 2025 | 29 | 3.270 |
Why?
|
| Humans | 697 | 2026 | 97893 | 3.200 |
Why?
|
| Tumor Microenvironment | 31 | 2026 | 618 | 3.200 |
Why?
|
| Radiation-Sensitizing Agents | 21 | 2026 | 98 | 3.130 |
Why?
|
| Dendritic Cells | 13 | 2025 | 552 | 2.900 |
Why?
|
| Cell Line, Tumor | 87 | 2026 | 2892 | 2.860 |
Why?
|
| DNA Damage | 57 | 2025 | 399 | 2.770 |
Why?
|
| RNA-Binding Proteins | 7 | 2025 | 324 | 2.750 |
Why?
|
| Antineoplastic Agents | 55 | 2026 | 2373 | 2.680 |
Why?
|
| Interferon Type I | 11 | 2026 | 170 | 2.600 |
Why?
|
| Nanoparticles | 16 | 2025 | 218 | 2.580 |
Why?
|
| Metal-Organic Frameworks | 15 | 2026 | 24 | 2.540 |
Why?
|
| Tumor Cells, Cultured | 105 | 2018 | 1028 | 2.510 |
Why?
|
| Gene Expression Regulation, Neoplastic | 46 | 2021 | 1394 | 2.480 |
Why?
|
| Neoplasms, Experimental | 26 | 2019 | 263 | 2.340 |
Why?
|
| Lung Neoplasms | 42 | 2026 | 2457 | 2.320 |
Why?
|
| Herpesvirus 1, Human | 20 | 2015 | 210 | 2.250 |
Why?
|
| MicroRNAs | 13 | 2023 | 604 | 2.230 |
Why?
|
| Cell Survival | 97 | 2020 | 1014 | 2.190 |
Why?
|
| Adenocarcinoma | 31 | 2019 | 1211 | 2.170 |
Why?
|
| Mice, Nude | 59 | 2020 | 830 | 2.110 |
Why?
|
| Apoptosis | 55 | 2024 | 1752 | 2.100 |
Why?
|
| Signal Transduction | 50 | 2026 | 3623 | 2.080 |
Why?
|
| Glioma | 19 | 2021 | 309 | 2.080 |
Why?
|
| Amphiregulin | 3 | 2025 | 17 | 2.040 |
Why?
|
| Pancreatic Neoplasms | 13 | 2026 | 769 | 2.020 |
Why?
|
| Membrane Proteins | 14 | 2024 | 1285 | 2.000 |
Why?
|
| B7-H1 Antigen | 19 | 2025 | 332 | 1.960 |
Why?
|
| NF-kappa B | 14 | 2023 | 423 | 1.940 |
Why?
|
| DNA Repair | 51 | 2025 | 363 | 1.930 |
Why?
|
| Radiation Oncology | 9 | 2026 | 130 | 1.880 |
Why?
|
| Breast Neoplasms | 51 | 2025 | 3272 | 1.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 75 | 2023 | 2658 | 1.840 |
Why?
|
| Colorectal Neoplasms | 19 | 2023 | 1103 | 1.830 |
Why?
|
| Chemoradiotherapy | 14 | 2021 | 337 | 1.810 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2025 | 700 | 1.790 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2022 | 1173 | 1.750 |
Why?
|
| Xenograft Model Antitumor Assays | 24 | 2025 | 557 | 1.710 |
Why?
|
| Melanoma, Experimental | 7 | 2024 | 114 | 1.690 |
Why?
|
| DNA-Binding Proteins | 41 | 2021 | 1254 | 1.620 |
Why?
|
| Immediate-Early Proteins | 20 | 2005 | 161 | 1.610 |
Why?
|
| Brain Neoplasms | 21 | 2021 | 839 | 1.610 |
Why?
|
| Mucin-1 | 9 | 2015 | 46 | 1.600 |
Why?
|
| Endothelium, Vascular | 18 | 2013 | 440 | 1.570 |
Why?
|
| Prostatic Neoplasms | 36 | 2023 | 1836 | 1.570 |
Why?
|
| Mice, Inbred C57BL | 50 | 2025 | 3605 | 1.510 |
Why?
|
| Female | 276 | 2025 | 51463 | 1.500 |
Why?
|
| Adenoviridae | 22 | 2013 | 340 | 1.480 |
Why?
|
| Liver Neoplasms | 13 | 2026 | 826 | 1.410 |
Why?
|
| Oncolytic Virotherapy | 6 | 2014 | 36 | 1.360 |
Why?
|
| Dose-Response Relationship, Radiation | 54 | 2018 | 193 | 1.350 |
Why?
|
| Colonic Neoplasms | 14 | 2025 | 582 | 1.320 |
Why?
|
| Neoplasm Transplantation | 38 | 2019 | 400 | 1.300 |
Why?
|
| Peptide Fragments | 14 | 2003 | 479 | 1.260 |
Why?
|
| Sarcoma | 14 | 2013 | 222 | 1.250 |
Why?
|
| T-Lymphocytes | 8 | 2026 | 1331 | 1.250 |
Why?
|
| Biomarkers, Tumor | 11 | 2025 | 1764 | 1.240 |
Why?
|
| Immunity, Innate | 12 | 2024 | 481 | 1.230 |
Why?
|
| Plasminogen | 10 | 2003 | 45 | 1.220 |
Why?
|
| Transforming Growth Factor beta | 5 | 2023 | 356 | 1.200 |
Why?
|
| Transcription, Genetic | 30 | 2020 | 1133 | 1.190 |
Why?
|
| Myeloid-Derived Suppressor Cells | 4 | 2025 | 31 | 1.180 |
Why?
|
| Genetic Vectors | 30 | 2017 | 426 | 1.170 |
Why?
|
| Gene Expression Regulation | 27 | 2023 | 2023 | 1.160 |
Why?
|
| Neovascularization, Pathologic | 12 | 2013 | 356 | 1.140 |
Why?
|
| Transcription Factors | 26 | 2023 | 1717 | 1.130 |
Why?
|
| Glioblastoma | 14 | 2021 | 299 | 1.130 |
Why?
|
| Cross-Priming | 6 | 2025 | 59 | 1.130 |
Why?
|
| STAT1 Transcription Factor | 9 | 2017 | 60 | 1.120 |
Why?
|
| Radiation Injuries, Experimental | 9 | 2015 | 41 | 1.100 |
Why?
|
| Radiotherapy Dosage | 48 | 2020 | 479 | 1.090 |
Why?
|
| Enzyme Inhibitors | 11 | 2025 | 642 | 1.070 |
Why?
|
| Cisplatin | 53 | 2013 | 578 | 1.040 |
Why?
|
| Cell Proliferation | 16 | 2020 | 1790 | 1.040 |
Why?
|
| Male | 213 | 2025 | 46995 | 1.000 |
Why?
|
| Enzyme Activation | 38 | 2013 | 679 | 0.990 |
Why?
|
| Cell Line | 96 | 2012 | 2483 | 0.980 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 8 | 2022 | 88 | 0.970 |
Why?
|
| Survival Rate | 39 | 2021 | 2040 | 0.960 |
Why?
|
| Cellular Senescence | 8 | 2025 | 110 | 0.960 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2021 | 665 | 0.960 |
Why?
|
| Benzimidazoles | 3 | 2012 | 118 | 0.950 |
Why?
|
| DNA, Neoplasm | 21 | 2015 | 267 | 0.950 |
Why?
|
| Photochemotherapy | 6 | 2025 | 101 | 0.930 |
Why?
|
| Adaptive Immunity | 11 | 2024 | 193 | 0.930 |
Why?
|
| Genes, p53 | 12 | 2011 | 108 | 0.930 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2026 | 23 | 0.930 |
Why?
|
| RNA Helicases | 3 | 2023 | 45 | 0.930 |
Why?
|
| Melanoma | 18 | 2021 | 524 | 0.910 |
Why?
|
| Dacarbazine | 6 | 2015 | 104 | 0.910 |
Why?
|
| Fluorouracil | 47 | 2023 | 541 | 0.910 |
Why?
|
| ErbB Receptors | 9 | 2025 | 516 | 0.890 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2019 | 136 | 0.890 |
Why?
|
| Neoplasm Staging | 52 | 2021 | 2080 | 0.880 |
Why?
|
| Neoplasm Recurrence, Local | 35 | 2023 | 1536 | 0.870 |
Why?
|
| Protein Kinase C | 22 | 2000 | 267 | 0.870 |
Why?
|
| Prognosis | 55 | 2025 | 4112 | 0.860 |
Why?
|
| DNA | 31 | 2018 | 1274 | 0.860 |
Why?
|
| Chemokine CCL22 | 1 | 2024 | 9 | 0.860 |
Why?
|
| Mice, Knockout | 24 | 2024 | 2208 | 0.850 |
Why?
|
| Radiobiology | 5 | 2026 | 15 | 0.840 |
Why?
|
| Nanostructures | 4 | 2024 | 93 | 0.830 |
Why?
|
| Disease Models, Animal | 22 | 2024 | 2572 | 0.810 |
Why?
|
| Simplexvirus | 10 | 2012 | 66 | 0.800 |
Why?
|
| Middle Aged | 156 | 2024 | 29352 | 0.800 |
Why?
|
| Virus Replication | 15 | 2014 | 292 | 0.790 |
Why?
|
| Palliative Care | 9 | 2019 | 289 | 0.790 |
Why?
|
| Aged | 127 | 2024 | 21701 | 0.790 |
Why?
|
| Survival Analysis | 26 | 2020 | 1527 | 0.780 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2016 | 401 | 0.780 |
Why?
|
| Cells, Cultured | 48 | 2021 | 2855 | 0.760 |
Why?
|
| NF-kappa B p50 Subunit | 7 | 2020 | 38 | 0.760 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 212 | 0.750 |
Why?
|
| Disease-Free Survival | 29 | 2018 | 1193 | 0.750 |
Why?
|
| Gene Expression | 23 | 2015 | 1320 | 0.750 |
Why?
|
| Radiation-Protective Agents | 12 | 2015 | 98 | 0.740 |
Why?
|
| Fibrosarcoma | 7 | 2020 | 89 | 0.740 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 11 | 2012 | 700 | 0.730 |
Why?
|
| Cancer Vaccines | 4 | 2020 | 168 | 0.730 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2026 | 358 | 0.720 |
Why?
|
| Polymers | 8 | 2025 | 224 | 0.720 |
Why?
|
| Light | 2 | 2022 | 289 | 0.710 |
Why?
|
| Interferons | 3 | 2012 | 114 | 0.700 |
Why?
|
| Inflammation | 9 | 2023 | 1120 | 0.700 |
Why?
|
| Radioimmunodetection | 4 | 2008 | 12 | 0.700 |
Why?
|
| Reactive Oxygen Species | 15 | 2025 | 525 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 14 | 2019 | 462 | 0.690 |
Why?
|
| Interferon-gamma | 11 | 2021 | 479 | 0.690 |
Why?
|
| Tumor Burden | 11 | 2024 | 330 | 0.690 |
Why?
|
| Repressor Proteins | 6 | 2020 | 448 | 0.670 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2020 | 200 | 0.670 |
Why?
|
| Transplantation, Heterologous | 22 | 2010 | 375 | 0.660 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.660 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 582 | 0.660 |
Why?
|
| Inhibitor of Apoptosis Proteins | 5 | 2017 | 33 | 0.650 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2018 | 902 | 0.650 |
Why?
|
| Acetophenones | 1 | 2020 | 27 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-abl | 18 | 2005 | 30 | 0.640 |
Why?
|
| Butyrates | 1 | 2021 | 62 | 0.640 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 244 | 0.640 |
Why?
|
| Lung | 9 | 2015 | 1406 | 0.640 |
Why?
|
| Early Growth Response Protein 1 | 18 | 2007 | 58 | 0.640 |
Why?
|
| CTLA-4 Antigen | 2 | 2024 | 146 | 0.630 |
Why?
|
| Radiation Dosage | 10 | 2020 | 231 | 0.630 |
Why?
|
| Mutation | 25 | 2020 | 4396 | 0.630 |
Why?
|
| Hydroxyurea | 27 | 2012 | 233 | 0.630 |
Why?
|
| Gene Transfer Techniques | 9 | 2019 | 155 | 0.630 |
Why?
|
| Cytoskeleton | 3 | 2020 | 200 | 0.630 |
Why?
|
| Oxygen | 9 | 2026 | 772 | 0.630 |
Why?
|
| Promoter Regions, Genetic | 19 | 2021 | 977 | 0.620 |
Why?
|
| Actomyosin | 1 | 2020 | 52 | 0.620 |
Why?
|
| Drug Repositioning | 2 | 2019 | 33 | 0.610 |
Why?
|
| Treatment Outcome | 51 | 2021 | 9682 | 0.610 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 105 | 0.610 |
Why?
|
| Viral Proteins | 8 | 2007 | 252 | 0.610 |
Why?
|
| Neoplasm Proteins | 8 | 2009 | 551 | 0.600 |
Why?
|
| Gene Amplification | 2 | 2018 | 142 | 0.600 |
Why?
|
| Carcinoma, Lewis Lung | 6 | 2003 | 25 | 0.600 |
Why?
|
| Adult | 127 | 2024 | 29453 | 0.600 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 95 | 0.600 |
Why?
|
| Disease Progression | 14 | 2025 | 1609 | 0.590 |
Why?
|
| Tunica Intima | 5 | 2015 | 61 | 0.590 |
Why?
|
| Gene Expression Profiling | 16 | 2020 | 1565 | 0.590 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2021 | 660 | 0.580 |
Why?
|
| Myeloid Cells | 4 | 2025 | 121 | 0.580 |
Why?
|
| CD47 Antigen | 4 | 2025 | 26 | 0.580 |
Why?
|
| Radiation Injuries | 12 | 2014 | 160 | 0.580 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2018 | 50 | 0.580 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 216 | 0.580 |
Why?
|
| Time Factors | 52 | 2017 | 5555 | 0.580 |
Why?
|
| Mitochondria | 6 | 2025 | 650 | 0.570 |
Why?
|
| Aged, 80 and over | 45 | 2021 | 7386 | 0.570 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2015 | 135 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 341 | 0.550 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 337 | 0.550 |
Why?
|
| X-Rays | 36 | 2024 | 139 | 0.540 |
Why?
|
| Down-Regulation | 13 | 2025 | 529 | 0.540 |
Why?
|
| Cell Cycle | 23 | 2020 | 518 | 0.540 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 168 | 0.540 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2018 | 323 | 0.530 |
Why?
|
| Muscle, Smooth, Vascular | 6 | 2015 | 234 | 0.530 |
Why?
|
| Endothelial Cells | 7 | 2022 | 500 | 0.530 |
Why?
|
| Paclitaxel | 14 | 2013 | 483 | 0.530 |
Why?
|
| Hodgkin Disease | 10 | 1995 | 144 | 0.530 |
Why?
|
| Retinoblastoma | 16 | 1988 | 30 | 0.520 |
Why?
|
| Nuclear Proteins | 15 | 2015 | 750 | 0.520 |
Why?
|
| Eye Neoplasms | 15 | 1988 | 25 | 0.510 |
Why?
|
| Transfection | 22 | 2009 | 883 | 0.510 |
Why?
|
| Ceramides | 7 | 2011 | 36 | 0.510 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2022 | 682 | 0.510 |
Why?
|
| Follow-Up Studies | 41 | 2021 | 4023 | 0.500 |
Why?
|
| RNA | 5 | 2023 | 595 | 0.500 |
Why?
|
| Cholesterol | 6 | 2024 | 373 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 1416 | 0.490 |
Why?
|
| Laryngeal Neoplasms | 13 | 2002 | 89 | 0.490 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2015 | 65 | 0.480 |
Why?
|
| Carcinoma | 9 | 2014 | 440 | 0.480 |
Why?
|
| Cephalosporins | 1 | 2016 | 25 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 26 | 2016 | 1946 | 0.480 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2014 | 280 | 0.480 |
Why?
|
| Immunologic Factors | 6 | 2022 | 179 | 0.480 |
Why?
|
| Clinical Trials as Topic | 20 | 2020 | 1125 | 0.470 |
Why?
|
| HCT116 Cells | 7 | 2020 | 163 | 0.470 |
Why?
|
| Macrophages | 6 | 2021 | 643 | 0.470 |
Why?
|
| Fibroblasts | 32 | 2020 | 767 | 0.470 |
Why?
|
| Prostate-Specific Antigen | 14 | 2010 | 354 | 0.470 |
Why?
|
| Indoles | 3 | 2023 | 334 | 0.460 |
Why?
|
| Adenosine | 3 | 2025 | 291 | 0.460 |
Why?
|
| Nucleotidyltransferases | 2 | 2017 | 32 | 0.460 |
Why?
|
| Tumor Hypoxia | 4 | 2026 | 53 | 0.460 |
Why?
|
| Prodrugs | 5 | 2023 | 53 | 0.460 |
Why?
|
| Tamoxifen | 7 | 2012 | 176 | 0.460 |
Why?
|
| Recombinant Fusion Proteins | 14 | 2010 | 557 | 0.450 |
Why?
|
| Superoxide Dismutase | 3 | 2012 | 155 | 0.450 |
Why?
|
| Risk Assessment | 9 | 2020 | 2580 | 0.440 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 1605 | 0.440 |
Why?
|
| Copper | 3 | 2024 | 81 | 0.440 |
Why?
|
| Cell Division | 19 | 2004 | 689 | 0.440 |
Why?
|
| Doxorubicin | 12 | 2009 | 285 | 0.440 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 68 | 0.440 |
Why?
|
| Vaccination | 2 | 2020 | 323 | 0.440 |
Why?
|
| Cell Movement | 9 | 2020 | 815 | 0.440 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2015 | 44 | 0.440 |
Why?
|
| Pandemics | 2 | 2020 | 913 | 0.440 |
Why?
|
| Genomic Instability | 6 | 2020 | 90 | 0.430 |
Why?
|
| Neoplasms, Radiation-Induced | 7 | 1995 | 96 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2020 | 324 | 0.430 |
Why?
|
| Radiotherapy, Image-Guided | 4 | 2018 | 66 | 0.430 |
Why?
|
| Radiotherapy, Conformal | 5 | 2009 | 88 | 0.430 |
Why?
|
| Genes, jun | 7 | 1996 | 18 | 0.430 |
Why?
|
| Sphingosine | 6 | 2013 | 73 | 0.430 |
Why?
|
| CDC2 Protein Kinase | 9 | 2021 | 46 | 0.420 |
Why?
|
| X-Ray Therapy | 2 | 2018 | 7 | 0.420 |
Why?
|
| Patient Selection | 4 | 2014 | 720 | 0.420 |
Why?
|
| Rad51 Recombinase | 12 | 2015 | 81 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2018 | 400 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2026 | 156 | 0.410 |
Why?
|
| Guanine | 2 | 2007 | 194 | 0.410 |
Why?
|
| Drug Synergism | 12 | 2020 | 317 | 0.410 |
Why?
|
| Chemotherapy, Adjuvant | 17 | 2015 | 525 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 983 | 0.410 |
Why?
|
| Interferon-beta | 5 | 2016 | 127 | 0.400 |
Why?
|
| Biomarkers | 7 | 2022 | 2016 | 0.400 |
Why?
|
| RNA, Messenger | 17 | 2025 | 2063 | 0.390 |
Why?
|
| Chromosome Aberrations | 10 | 1999 | 352 | 0.390 |
Why?
|
| Rats | 23 | 2019 | 4071 | 0.380 |
Why?
|
| Benzamides | 8 | 2014 | 260 | 0.380 |
Why?
|
| Lymphocyte Activation | 5 | 2025 | 822 | 0.380 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 349 | 0.380 |
Why?
|
| Cytokines | 11 | 2023 | 889 | 0.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 159 | 0.370 |
Why?
|
| Radioisotopes | 3 | 2023 | 41 | 0.370 |
Why?
|
| Probiotics | 2 | 2026 | 99 | 0.370 |
Why?
|
| Lymphocytes | 7 | 2018 | 461 | 0.370 |
Why?
|
| Phosphorylation | 29 | 2017 | 1145 | 0.370 |
Why?
|
| Angiostatins | 10 | 2003 | 15 | 0.370 |
Why?
|
| Isoenzymes | 9 | 2000 | 272 | 0.370 |
Why?
|
| Phenanthridines | 5 | 2000 | 25 | 0.360 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 41 | 0.360 |
Why?
|
| Collagen | 6 | 2019 | 313 | 0.360 |
Why?
|
| Methotrexate | 29 | 1994 | 227 | 0.350 |
Why?
|
| Mice, Inbred BALB C | 13 | 2023 | 1110 | 0.350 |
Why?
|
| Cell Death | 7 | 2018 | 257 | 0.350 |
Why?
|
| Metal Nanoparticles | 2 | 2026 | 37 | 0.350 |
Why?
|
| Recombinant Proteins | 22 | 2011 | 993 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2023 | 1098 | 0.350 |
Why?
|
| Papillomaviridae | 5 | 2014 | 184 | 0.350 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 221 | 0.350 |
Why?
|
| eIF-2 Kinase | 2 | 2015 | 52 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2020 | 312 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 872 | 0.340 |
Why?
|
| Radiotherapy, Computer-Assisted | 3 | 2008 | 25 | 0.340 |
Why?
|
| Tumor Virus Infections | 4 | 2014 | 83 | 0.340 |
Why?
|
| Epigenesis, Genetic | 3 | 2023 | 588 | 0.340 |
Why?
|
| Drug Delivery Systems | 7 | 2025 | 200 | 0.340 |
Why?
|
| Transcriptional Activation | 8 | 2015 | 293 | 0.340 |
Why?
|
| Chromosome Deletion | 12 | 1993 | 214 | 0.340 |
Why?
|
| Retrospective Studies | 34 | 2023 | 10947 | 0.330 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2025 | 44 | 0.330 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2025 | 332 | 0.330 |
Why?
|
| Carotid Arteries | 1 | 2012 | 132 | 0.330 |
Why?
|
| Sulfonamides | 4 | 2018 | 351 | 0.330 |
Why?
|
| Transcription Factor RelA | 3 | 2018 | 39 | 0.330 |
Why?
|
| DNA, Complementary | 8 | 2007 | 380 | 0.330 |
Why?
|
| Immunoglobulin G | 2 | 2010 | 480 | 0.330 |
Why?
|
| DNA Replication | 8 | 2017 | 169 | 0.330 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.320 |
Why?
|
| Lymphokines | 2 | 2002 | 74 | 0.320 |
Why?
|
| Gamma Rays | 15 | 2018 | 72 | 0.320 |
Why?
|
| Bacteria | 3 | 2025 | 545 | 0.320 |
Why?
|
| Cell Nucleus | 15 | 2002 | 615 | 0.320 |
Why?
|
| Brachytherapy | 4 | 2010 | 139 | 0.310 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2025 | 153 | 0.310 |
Why?
|
| Ligands | 4 | 2025 | 487 | 0.310 |
Why?
|
| DEAD Box Protein 58 | 3 | 2020 | 12 | 0.310 |
Why?
|
| Histones | 5 | 2025 | 370 | 0.310 |
Why?
|
| MCF-7 Cells | 7 | 2020 | 123 | 0.300 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 92 | 0.300 |
Why?
|
| Proportional Hazards Models | 11 | 2018 | 920 | 0.300 |
Why?
|
| Predictive Value of Tests | 7 | 2015 | 1778 | 0.300 |
Why?
|
| Stress, Physiological | 6 | 2014 | 256 | 0.300 |
Why?
|
| Electron Spin Resonance Spectroscopy | 7 | 2026 | 337 | 0.300 |
Why?
|
| Receptors, Pattern Recognition | 2 | 2020 | 20 | 0.300 |
Why?
|
| Sequence Deletion | 2 | 2007 | 207 | 0.290 |
Why?
|
| Zinc Compounds | 3 | 2025 | 6 | 0.290 |
Why?
|
| Neuroendocrine Tumors | 2 | 2022 | 157 | 0.290 |
Why?
|
| Up-Regulation | 8 | 2018 | 743 | 0.290 |
Why?
|
| Sphingomyelin Phosphodiesterase | 5 | 2013 | 20 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 7 | 2022 | 478 | 0.280 |
Why?
|
| Deoxycytidine | 3 | 2007 | 217 | 0.280 |
Why?
|
| Lymphatic Metastasis | 14 | 2018 | 520 | 0.280 |
Why?
|
| Bifidobacterium | 2 | 2026 | 21 | 0.280 |
Why?
|
| In Vitro Techniques | 25 | 2007 | 945 | 0.280 |
Why?
|
| Phenotype | 11 | 2025 | 2638 | 0.280 |
Why?
|
| Cyclophosphamide | 8 | 2005 | 284 | 0.280 |
Why?
|
| Necrosis | 11 | 2018 | 210 | 0.280 |
Why?
|
| Mouth Neoplasms | 8 | 2017 | 222 | 0.280 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 142 | 0.280 |
Why?
|
| Methylation | 4 | 2025 | 294 | 0.280 |
Why?
|
| Drug Administration Schedule | 22 | 2003 | 836 | 0.270 |
Why?
|
| Proto-Oncogenes | 8 | 1995 | 60 | 0.270 |
Why?
|
| Osteosarcoma | 13 | 1990 | 157 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2006 | 100 | 0.270 |
Why?
|
| Gene Regulatory Networks | 3 | 2012 | 337 | 0.270 |
Why?
|
| Stilbenes | 1 | 2007 | 26 | 0.270 |
Why?
|
| Nanomedicine | 3 | 2018 | 19 | 0.270 |
Why?
|
| Cytochrome c Group | 4 | 2000 | 82 | 0.270 |
Why?
|
| Metastasectomy | 2 | 2020 | 10 | 0.270 |
Why?
|
| Toll-Like Receptor 3 | 2 | 2025 | 16 | 0.270 |
Why?
|
| Bleomycin | 14 | 2015 | 102 | 0.270 |
Why?
|
| RNA, Small Interfering | 7 | 2017 | 564 | 0.270 |
Why?
|
| Leucovorin | 24 | 2003 | 205 | 0.260 |
Why?
|
| Viruses | 3 | 2007 | 64 | 0.260 |
Why?
|
| Models, Biological | 13 | 2020 | 1806 | 0.260 |
Why?
|
| Multivariate Analysis | 12 | 2018 | 1009 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 977 | 0.260 |
Why?
|
| Prostatectomy | 5 | 2008 | 490 | 0.260 |
Why?
|
| Base Sequence | 18 | 2021 | 2222 | 0.260 |
Why?
|
| Rabbits | 10 | 2015 | 581 | 0.260 |
Why?
|
| Esophageal Neoplasms | 7 | 2005 | 353 | 0.260 |
Why?
|
| Transduction, Genetic | 3 | 2004 | 161 | 0.260 |
Why?
|
| Platinum | 3 | 2026 | 68 | 0.260 |
Why?
|
| Antigens, Neoplasm | 8 | 2023 | 365 | 0.260 |
Why?
|
| Skin | 10 | 2024 | 591 | 0.250 |
Why?
|
| Mercaptoethylamines | 5 | 2012 | 52 | 0.250 |
Why?
|
| Phagocytosis | 2 | 2025 | 117 | 0.250 |
Why?
|
| Ataxia Telangiectasia | 7 | 1996 | 12 | 0.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2024 | 200 | 0.250 |
Why?
|
| Diagnostic Imaging | 4 | 2015 | 467 | 0.250 |
Why?
|
| Sister Chromatid Exchange | 6 | 1989 | 12 | 0.250 |
Why?
|
| Protein-Tyrosine Kinases | 11 | 2000 | 304 | 0.250 |
Why?
|
| Surface-Active Agents | 5 | 2011 | 58 | 0.250 |
Why?
|
| G2 Phase | 5 | 2000 | 32 | 0.250 |
Why?
|
| Papillomavirus Infections | 5 | 2020 | 311 | 0.250 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2005 | 123 | 0.250 |
Why?
|
| Molecular Sequence Data | 25 | 2009 | 2896 | 0.250 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2020 | 80 | 0.250 |
Why?
|
| Cohort Studies | 13 | 2020 | 3202 | 0.240 |
Why?
|
| Neurofibromatosis 1 | 2 | 2026 | 44 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinases | 8 | 2002 | 218 | 0.240 |
Why?
|
| Cell Adhesion | 7 | 2020 | 419 | 0.240 |
Why?
|
| Veratrum Alkaloids | 1 | 2006 | 9 | 0.240 |
Why?
|
| Adolescent | 40 | 2020 | 10078 | 0.240 |
Why?
|
| Administration, Oral | 6 | 2021 | 674 | 0.240 |
Why?
|
| Oncolytic Viruses | 4 | 2014 | 20 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2009 | 461 | 0.240 |
Why?
|
| Transplantation Conditioning | 3 | 2020 | 388 | 0.240 |
Why?
|
| Organometallic Compounds | 2 | 2025 | 142 | 0.240 |
Why?
|
| Cell Hypoxia | 4 | 2017 | 191 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2012 | 321 | 0.240 |
Why?
|
| Postoperative Care | 3 | 2004 | 236 | 0.240 |
Why?
|
| Acetylcysteine | 5 | 2017 | 73 | 0.240 |
Why?
|
| DNA Helicases | 3 | 2015 | 91 | 0.230 |
Why?
|
| Chromosomes, Human, 13-15 | 10 | 1986 | 18 | 0.230 |
Why?
|
| Interleukin-2 | 1 | 2026 | 246 | 0.230 |
Why?
|
| Bone Marrow Transplantation | 3 | 1995 | 286 | 0.230 |
Why?
|
| Trans-Activators | 3 | 2004 | 447 | 0.230 |
Why?
|
| Binding Sites | 12 | 2021 | 1159 | 0.230 |
Why?
|
| Microbiota | 2 | 2024 | 467 | 0.230 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2025 | 10 | 0.230 |
Why?
|
| Umbilical Veins | 6 | 2004 | 45 | 0.230 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 104 | 0.230 |
Why?
|
| RNA, Neoplasm | 9 | 2000 | 87 | 0.220 |
Why?
|
| Hyperplasia | 7 | 2015 | 148 | 0.220 |
Why?
|
| Genes, Immediate-Early | 2 | 1995 | 17 | 0.220 |
Why?
|
| Neutrons | 2 | 1995 | 57 | 0.220 |
Why?
|
| Mice, SCID | 2 | 2016 | 278 | 0.220 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 383 | 0.220 |
Why?
|
| Remission Induction | 17 | 2003 | 754 | 0.220 |
Why?
|
| Aneuploidy | 1 | 2025 | 60 | 0.220 |
Why?
|
| Human papillomavirus 16 | 3 | 2020 | 46 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2023 | 110 | 0.220 |
Why?
|
| Ultrasonic Therapy | 1 | 2025 | 44 | 0.220 |
Why?
|
| Poly I-C | 2 | 2025 | 20 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 6 | 2017 | 265 | 0.220 |
Why?
|
| Poloxamer | 4 | 2011 | 24 | 0.220 |
Why?
|
| Immunoblotting | 12 | 2017 | 274 | 0.220 |
Why?
|
| Cell Communication | 2 | 2003 | 223 | 0.220 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2024 | 31 | 0.210 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2013 | 64 | 0.210 |
Why?
|
| Immunity | 3 | 2022 | 160 | 0.210 |
Why?
|
| Intestines | 2 | 2019 | 441 | 0.210 |
Why?
|
| Enterococcus faecalis | 2 | 2022 | 58 | 0.210 |
Why?
|
| Coumarins | 2 | 2001 | 15 | 0.210 |
Why?
|
| Skull Neoplasms | 4 | 1995 | 25 | 0.210 |
Why?
|
| Zinc | 2 | 2022 | 99 | 0.210 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2017 | 73 | 0.210 |
Why?
|
| Treatment Failure | 8 | 2015 | 299 | 0.210 |
Why?
|
| Ovarian Neoplasms | 5 | 2025 | 826 | 0.210 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2025 | 92 | 0.210 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2004 | 12 | 0.210 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 218 | 0.210 |
Why?
|
| Flow Cytometry | 5 | 2016 | 720 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 6 | 1999 | 126 | 0.210 |
Why?
|
| Genes, Dominant | 1 | 2004 | 111 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 111 | 0.200 |
Why?
|
| Recurrence | 11 | 2017 | 1254 | 0.200 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2020 | 31 | 0.200 |
Why?
|
| src-Family Kinases | 6 | 2002 | 70 | 0.200 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2020 | 34 | 0.200 |
Why?
|
| Lymph Nodes | 8 | 2018 | 560 | 0.200 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2003 | 48 | 0.200 |
Why?
|
| Pulmonary Fibrosis | 3 | 2015 | 158 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 639 | 0.200 |
Why?
|
| Tretinoin | 2 | 2021 | 130 | 0.200 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.200 |
Why?
|
| Dysbiosis | 1 | 2024 | 101 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 176 | 0.200 |
Why?
|
| Erythropoietin | 2 | 2003 | 90 | 0.200 |
Why?
|
| Immunohistochemistry | 11 | 2017 | 1815 | 0.200 |
Why?
|
| Diet, Western | 2 | 2023 | 45 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2003 | 158 | 0.190 |
Why?
|
| Medical Oncology | 2 | 2020 | 421 | 0.190 |
Why?
|
| Gastrointestinal Tract | 3 | 2021 | 198 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 321 | 0.190 |
Why?
|
| Caspases | 6 | 2009 | 151 | 0.190 |
Why?
|
| Adenine | 1 | 2023 | 101 | 0.190 |
Why?
|
| Colorectal Surgery | 1 | 2023 | 25 | 0.190 |
Why?
|
| Hepatectomy | 2 | 2014 | 202 | 0.190 |
Why?
|
| S Phase | 5 | 2015 | 64 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 3 | 2021 | 512 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 31 | 0.190 |
Why?
|
| Photosensitizing Agents | 4 | 2025 | 53 | 0.190 |
Why?
|
| Cyclic AMP | 2 | 2022 | 277 | 0.190 |
Why?
|
| Genetic Engineering | 4 | 2025 | 102 | 0.190 |
Why?
|
| Sepsis | 3 | 2020 | 401 | 0.190 |
Why?
|
| Lung Injury | 2 | 2015 | 61 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 2 | 2013 | 37 | 0.190 |
Why?
|
| Acute Lung Injury | 2 | 2013 | 73 | 0.180 |
Why?
|
| Caspase 3 | 8 | 2017 | 161 | 0.180 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 419 | 0.180 |
Why?
|
| Stem Cells | 1 | 2005 | 396 | 0.180 |
Why?
|
| Tumor Escape | 3 | 2017 | 55 | 0.180 |
Why?
|
| Human papillomavirus 18 | 2 | 2020 | 22 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2010 | 85 | 0.180 |
Why?
|
| Receptors, LDL | 1 | 2022 | 54 | 0.180 |
Why?
|
| Immune Tolerance | 1 | 2025 | 386 | 0.180 |
Why?
|
| Herpes Simplex Virus Vaccines | 1 | 2002 | 2 | 0.180 |
Why?
|
| Autoradiography | 3 | 2001 | 51 | 0.180 |
Why?
|
| Neutrophils | 3 | 2021 | 345 | 0.180 |
Why?
|
| Lysophospholipids | 2 | 2013 | 67 | 0.180 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 23 | 0.180 |
Why?
|
| Herpesvirus 2, Human | 1 | 2002 | 21 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2021 | 4798 | 0.180 |
Why?
|
| Heat-Shock Proteins | 2 | 2000 | 178 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2018 | 373 | 0.180 |
Why?
|
| Folic Acid Antagonists | 1 | 2001 | 17 | 0.180 |
Why?
|
| Estrogens | 3 | 2020 | 202 | 0.170 |
Why?
|
| Bone Neoplasms | 9 | 1991 | 316 | 0.170 |
Why?
|
| Nucleoside Deaminases | 3 | 2000 | 3 | 0.170 |
Why?
|
| Homologous Recombination | 3 | 2017 | 57 | 0.170 |
Why?
|
| RNA Interference | 4 | 2015 | 388 | 0.170 |
Why?
|
| Protein Binding | 12 | 2015 | 1555 | 0.170 |
Why?
|
| Transforming Growth Factor alpha | 4 | 1998 | 49 | 0.170 |
Why?
|
| Flucytosine | 3 | 2000 | 11 | 0.170 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 382 | 0.170 |
Why?
|
| Glutamates | 1 | 2001 | 84 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2012 | 159 | 0.170 |
Why?
|
| Piperazines | 5 | 2024 | 306 | 0.170 |
Why?
|
| Interferon-alpha | 9 | 2011 | 191 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2020 | 188 | 0.170 |
Why?
|
| Alkylating Agents | 4 | 2012 | 32 | 0.170 |
Why?
|
| DNA Methylation | 3 | 2018 | 730 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 53 | 0.170 |
Why?
|
| Amifostine | 5 | 2011 | 50 | 0.170 |
Why?
|
| Tetradecanoylphorbol Acetate | 9 | 2007 | 122 | 0.170 |
Why?
|
| Heterografts | 3 | 2018 | 121 | 0.170 |
Why?
|
| Actins | 5 | 2020 | 480 | 0.170 |
Why?
|
| Coculture Techniques | 5 | 2021 | 175 | 0.170 |
Why?
|
| Vaginal Neoplasms | 2 | 2020 | 85 | 0.170 |
Why?
|
| Luciferases | 4 | 2015 | 128 | 0.170 |
Why?
|
| Mice, Inbred C3H | 8 | 2016 | 370 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 31 | 0.170 |
Why?
|
| Paraganglioma, Extra-Adrenal | 2 | 1991 | 11 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 108 | 0.160 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2020 | 10 | 0.160 |
Why?
|
| Rectum | 2 | 2004 | 150 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2021 | 38 | 0.160 |
Why?
|
| Chemokine CXCL10 | 2 | 2024 | 25 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 403 | 0.160 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 132 | 0.160 |
Why?
|
| Receptors, Estrogen | 9 | 2012 | 428 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1998 | 158 | 0.160 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2001 | 90 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-jun | 6 | 1995 | 34 | 0.160 |
Why?
|
| Nucleotides, Cyclic | 2 | 2024 | 13 | 0.160 |
Why?
|
| Genes, Regulator | 3 | 1998 | 60 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 169 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 1013 | 0.160 |
Why?
|
| Kinetics | 14 | 2001 | 1477 | 0.160 |
Why?
|
| Vancomycin | 1 | 2021 | 78 | 0.160 |
Why?
|
| Cell Differentiation | 7 | 2018 | 1646 | 0.160 |
Why?
|
| Drug Therapy | 4 | 2020 | 67 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2002 | 156 | 0.160 |
Why?
|
| Carcinogens | 1 | 2020 | 102 | 0.160 |
Why?
|
| Re-Irradiation | 1 | 2020 | 18 | 0.160 |
Why?
|
| Models, Theoretical | 4 | 2014 | 508 | 0.160 |
Why?
|
| Temporal Bone | 2 | 1991 | 65 | 0.160 |
Why?
|
| Aging | 4 | 2014 | 770 | 0.160 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 20 | 0.160 |
Why?
|
| Amino Acid Sequence | 14 | 2009 | 2007 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 53 | 0.160 |
Why?
|
| Leukemia | 4 | 1995 | 308 | 0.150 |
Why?
|
| Postoperative Complications | 6 | 2020 | 2680 | 0.150 |
Why?
|
| Risk Factors | 10 | 2020 | 6224 | 0.150 |
Why?
|
| DNA, Single-Stranded | 5 | 2008 | 95 | 0.150 |
Why?
|
| Oncogenes | 5 | 1995 | 102 | 0.150 |
Why?
|
| Extremities | 2 | 2004 | 173 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 505 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 1995 | 100 | 0.150 |
Why?
|
| Mastectomy, Segmental | 3 | 2010 | 115 | 0.150 |
Why?
|
| United States | 12 | 2025 | 8183 | 0.150 |
Why?
|
| Etanercept | 2 | 2010 | 37 | 0.150 |
Why?
|
| Clone Cells | 11 | 2020 | 220 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2020 | 88 | 0.150 |
Why?
|
| Sarcoma, Experimental | 5 | 2002 | 53 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2020 | 412 | 0.150 |
Why?
|
| Proteoglycans | 3 | 2000 | 76 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 109 | 0.150 |
Why?
|
| Antigen Presentation | 5 | 2023 | 234 | 0.150 |
Why?
|
| Safety | 1 | 2020 | 138 | 0.150 |
Why?
|
| Selection, Genetic | 1 | 2004 | 571 | 0.150 |
Why?
|
| Androgen Antagonists | 4 | 2009 | 157 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2019 | 1094 | 0.150 |
Why?
|
| Estradiol | 6 | 2012 | 268 | 0.150 |
Why?
|
| Mitomycin | 3 | 1994 | 30 | 0.150 |
Why?
|
| Laminin | 3 | 2000 | 89 | 0.150 |
Why?
|
| Ploidies | 1 | 1999 | 39 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 1999 | 110 | 0.140 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 22 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 8 | 2018 | 894 | 0.140 |
Why?
|
| Neck Dissection | 3 | 2014 | 67 | 0.140 |
Why?
|
| Oxidants | 2 | 2016 | 86 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2005 | 88 | 0.140 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2018 | 5 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 889 | 0.140 |
Why?
|
| Alkaloids | 6 | 2000 | 48 | 0.140 |
Why?
|
| ADP Ribose Transferases | 1 | 1998 | 7 | 0.140 |
Why?
|
| Exotoxins | 1 | 1998 | 21 | 0.140 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Protein Sorting Signals | 1 | 1998 | 42 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 168 | 0.140 |
Why?
|
| Cytarabine | 8 | 2000 | 218 | 0.140 |
Why?
|
| NADPH Oxidase 4 | 1 | 2018 | 15 | 0.140 |
Why?
|
| Adoptive Transfer | 2 | 2017 | 174 | 0.140 |
Why?
|
| Risk | 7 | 2020 | 660 | 0.140 |
Why?
|
| HeLa Cells | 7 | 2014 | 523 | 0.140 |
Why?
|
| Colectomy | 1 | 2019 | 201 | 0.140 |
Why?
|
| Keratinocytes | 2 | 2018 | 156 | 0.140 |
Why?
|
| Liposomes | 3 | 2010 | 104 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 112 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 59 | 0.130 |
Why?
|
| Virulence Factors | 1 | 1998 | 117 | 0.130 |
Why?
|
| Tongue Neoplasms | 2 | 2017 | 51 | 0.130 |
Why?
|
| Radiotherapy, High-Energy | 16 | 2010 | 43 | 0.130 |
Why?
|
| Isoquinolines | 3 | 1992 | 58 | 0.130 |
Why?
|
| Nanotechnology | 1 | 2018 | 74 | 0.130 |
Why?
|
| Organoids | 1 | 2018 | 91 | 0.130 |
Why?
|
| Lymphotoxin alpha1, beta2 Heterotrimer | 1 | 2017 | 4 | 0.130 |
Why?
|
| Pyrrolidines | 1 | 2018 | 61 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 106 | 0.130 |
Why?
|
| cdc25 Phosphatases | 2 | 2016 | 19 | 0.130 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2017 | 25 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 304 | 0.130 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2017 | 15 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 27 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 2 | 1997 | 125 | 0.130 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 125 | 0.130 |
Why?
|
| Cell Membrane | 5 | 2004 | 673 | 0.130 |
Why?
|
| Regression Analysis | 8 | 2017 | 577 | 0.130 |
Why?
|
| Genomics | 3 | 2026 | 898 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 24 | 0.130 |
Why?
|
| Craniocerebral Trauma | 1 | 1997 | 55 | 0.130 |
Why?
|
| Salvage Therapy | 4 | 2020 | 239 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2017 | 37 | 0.130 |
Why?
|
| Comorbidity | 3 | 2017 | 1032 | 0.130 |
Why?
|
| Karyotyping | 12 | 1993 | 220 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 4 | 2016 | 310 | 0.130 |
Why?
|
| Diphosphates | 1 | 2016 | 15 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 47 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2017 | 31 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2017 | 92 | 0.130 |
Why?
|
| Rectal Diseases | 1 | 1997 | 25 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1997 | 246 | 0.120 |
Why?
|
| fas Receptor | 1 | 2017 | 73 | 0.120 |
Why?
|
| Porphyrins | 1 | 2016 | 36 | 0.120 |
Why?
|
| Endoscopy | 1 | 2020 | 385 | 0.120 |
Why?
|
| Coordination Complexes | 1 | 2016 | 20 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 211 | 0.120 |
Why?
|
| Emodin | 1 | 2016 | 7 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 90 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2020 | 306 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2016 | 489 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 215 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 119 | 0.120 |
Why?
|
| Benzophenanthridines | 5 | 2000 | 23 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2000 | 212 | 0.120 |
Why?
|
| Receptors, Lysosphingolipid | 2 | 2013 | 38 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 403 | 0.120 |
Why?
|
| Pregnancy | 3 | 2013 | 3246 | 0.120 |
Why?
|
| Cat Diseases | 1 | 1996 | 19 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 79 | 0.120 |
Why?
|
| Homeostasis | 1 | 2018 | 474 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2013 | 3606 | 0.120 |
Why?
|
| Adenoviruses, Human | 3 | 2004 | 41 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2013 | 84 | 0.120 |
Why?
|
| Quality of Life | 8 | 2020 | 1891 | 0.120 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2013 | 75 | 0.120 |
Why?
|
| Blotting, Western | 5 | 2008 | 780 | 0.120 |
Why?
|
| Registries | 3 | 2017 | 1120 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2011 | 319 | 0.120 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Vero Cells | 2 | 2006 | 99 | 0.110 |
Why?
|
| Urinary Tract | 1 | 1996 | 34 | 0.110 |
Why?
|
| Urologic Diseases | 1 | 1996 | 38 | 0.110 |
Why?
|
| Spleen | 3 | 2012 | 375 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 206 | 0.110 |
Why?
|
| Cysteine Endopeptidases | 1 | 1995 | 89 | 0.110 |
Why?
|
| Morpholines | 1 | 2015 | 65 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 199 | 0.110 |
Why?
|
| Herpes Simplex | 3 | 2007 | 79 | 0.110 |
Why?
|
| Psoriasis | 1 | 2018 | 262 | 0.110 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2015 | 4 | 0.110 |
Why?
|
| Cystectomy | 2 | 2015 | 124 | 0.110 |
Why?
|
| Cricetinae | 14 | 1998 | 533 | 0.110 |
Why?
|
| Nucleic Acids | 1 | 2015 | 36 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 57 | 0.110 |
Why?
|
| Photons | 1 | 1995 | 52 | 0.110 |
Why?
|
| Ischemia | 1 | 2017 | 262 | 0.110 |
Why?
|
| Oligopeptides | 5 | 2000 | 206 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 189 | 0.110 |
Why?
|
| Glutamine | 1 | 2015 | 98 | 0.110 |
Why?
|
| Leukemia, Myeloid | 8 | 1996 | 241 | 0.110 |
Why?
|
| Xanthones | 1 | 2014 | 10 | 0.110 |
Why?
|
| Analysis of Variance | 8 | 2015 | 889 | 0.110 |
Why?
|
| Aging, Premature | 1 | 2014 | 6 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 1986 | 100 | 0.110 |
Why?
|
| Isoindoles | 2 | 2025 | 13 | 0.110 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 23 | 0.110 |
Why?
|
| Genes, Retinoblastoma | 2 | 1991 | 21 | 0.110 |
Why?
|
| Subcellular Fractions | 2 | 2007 | 84 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2015 | 452 | 0.110 |
Why?
|
| Injections, Intralesional | 3 | 1999 | 22 | 0.110 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2014 | 53 | 0.110 |
Why?
|
| Antioxidants | 2 | 2016 | 236 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2015 | 160 | 0.110 |
Why?
|
| Glycolysis | 1 | 2015 | 198 | 0.110 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2014 | 8 | 0.110 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 59 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 227 | 0.110 |
Why?
|
| Astrocytoma | 1 | 1995 | 85 | 0.110 |
Why?
|
| Ketoconazole | 1 | 1994 | 23 | 0.110 |
Why?
|
| Gene Deletion | 3 | 2015 | 353 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 49 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2015 | 110 | 0.100 |
Why?
|
| Second Messenger Systems | 1 | 1994 | 39 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 67 | 0.100 |
Why?
|
| Cloning, Molecular | 3 | 2001 | 582 | 0.100 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 1998 | 85 | 0.100 |
Why?
|
| Young Adult | 6 | 2020 | 7504 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 80 | 0.100 |
Why?
|
| Proteins | 6 | 2019 | 804 | 0.100 |
Why?
|
| Mitomycins | 4 | 1995 | 12 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 72 | 0.100 |
Why?
|
| Medulloblastoma | 4 | 1980 | 44 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1995 | 272 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 93 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 1995 | 138 | 0.100 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2013 | 3 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 8 | 0.100 |
Why?
|
| Population Groups | 1 | 2013 | 44 | 0.100 |
Why?
|
| Databases, Genetic | 2 | 2012 | 288 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 1993 | 69 | 0.100 |
Why?
|
| Translocation, Genetic | 3 | 1992 | 245 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 151 | 0.100 |
Why?
|
| Dexamethasone | 4 | 1992 | 318 | 0.100 |
Why?
|
| Male Urogenital Diseases | 2 | 2004 | 7 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2014 | 153 | 0.100 |
Why?
|
| Peptides | 5 | 2004 | 669 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 2 | 2023 | 176 | 0.100 |
Why?
|
| Propensity Score | 3 | 2020 | 213 | 0.100 |
Why?
|
| Propylene Glycols | 1 | 2013 | 30 | 0.100 |
Why?
|
| Whole-Body Irradiation | 5 | 2017 | 70 | 0.100 |
Why?
|
| Bromodeoxyuridine | 3 | 1988 | 53 | 0.100 |
Why?
|
| beta Catenin | 2 | 2019 | 267 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 369 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2014 | 144 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 53 | 0.090 |
Why?
|
| Mutagenesis | 2 | 2000 | 195 | 0.090 |
Why?
|
| Ethylnitrosourea | 1 | 2012 | 30 | 0.090 |
Why?
|
| DNA, Viral | 4 | 2005 | 238 | 0.090 |
Why?
|
| Protein Kinases | 9 | 2003 | 212 | 0.090 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 5 | 1996 | 26 | 0.090 |
Why?
|
| Drug Evaluation | 6 | 1992 | 109 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2011 | 22 | 0.090 |
Why?
|
| Infrared Rays | 2 | 2010 | 19 | 0.090 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 638 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2011 | 40 | 0.090 |
Why?
|
| Zinc Fingers | 4 | 1998 | 59 | 0.090 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2012 | 4 | 0.090 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2012 | 15 | 0.090 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 29 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 5 | 1982 | 44 | 0.090 |
Why?
|
| Genes, Viral | 3 | 2003 | 101 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 2 | 1990 | 195 | 0.090 |
Why?
|
| Radiation Effects | 3 | 1984 | 25 | 0.090 |
Why?
|
| Zidovudine | 1 | 1992 | 12 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2019 | 1255 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 3 | 2004 | 155 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 3 | 2014 | 435 | 0.090 |
Why?
|
| Plasmids | 4 | 2003 | 275 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 146 | 0.090 |
Why?
|
| Stromal Cells | 2 | 2017 | 153 | 0.090 |
Why?
|
| Mitosis | 3 | 2001 | 152 | 0.090 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 1999 | 30 | 0.090 |
Why?
|
| Defective Viruses | 3 | 2002 | 10 | 0.090 |
Why?
|
| Attitude to Health | 3 | 1991 | 217 | 0.090 |
Why?
|
| Orbital Neoplasms | 4 | 1992 | 16 | 0.090 |
Why?
|
| Sulfhydryl Compounds | 1 | 1992 | 67 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 256 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 1991 | 68 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 237 | 0.090 |
Why?
|
| Pleural Effusion | 2 | 2004 | 42 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 217 | 0.090 |
Why?
|
| Sphingolipids | 1 | 2011 | 21 | 0.090 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2000 | 61 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2011 | 80 | 0.080 |
Why?
|
| Fibroblast Growth Factors | 1 | 1992 | 89 | 0.080 |
Why?
|
| Protease Inhibitors | 2 | 2002 | 71 | 0.080 |
Why?
|
| Carboplatin | 5 | 2013 | 331 | 0.080 |
Why?
|
| ras Proteins | 1 | 2012 | 137 | 0.080 |
Why?
|
| Recombination, Genetic | 4 | 2004 | 424 | 0.080 |
Why?
|
| Child | 24 | 2016 | 7680 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 1991 | 26 | 0.080 |
Why?
|
| Genes | 2 | 1989 | 256 | 0.080 |
Why?
|
| Coitus | 1 | 1991 | 20 | 0.080 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2008 | 133 | 0.080 |
Why?
|
| DNA-Activated Protein Kinase | 5 | 2004 | 16 | 0.080 |
Why?
|
| Value of Life | 1 | 1991 | 23 | 0.080 |
Why?
|
| Child, Preschool | 14 | 2016 | 4000 | 0.080 |
Why?
|
| Social Values | 1 | 1991 | 44 | 0.080 |
Why?
|
| Pelvic Neoplasms | 2 | 1990 | 43 | 0.080 |
Why?
|
| Cell Membrane Permeability | 4 | 2000 | 121 | 0.080 |
Why?
|
| Iodine Radioisotopes | 4 | 2006 | 145 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 54 | 0.080 |
Why?
|
| Mesonephroma | 1 | 1990 | 4 | 0.080 |
Why?
|
| Antipain | 3 | 1985 | 3 | 0.080 |
Why?
|
| Vocal Cords | 2 | 1988 | 27 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2012 | 188 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 354 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 2 | 2000 | 9 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2011 | 399 | 0.080 |
Why?
|
| Vincristine | 7 | 1995 | 102 | 0.080 |
Why?
|
| Wound Healing | 4 | 2017 | 384 | 0.080 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2010 | 13 | 0.080 |
Why?
|
| Genotype | 3 | 2014 | 1888 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1990 | 64 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 182 | 0.080 |
Why?
|
| Alkylation | 3 | 2020 | 31 | 0.080 |
Why?
|
| Enzyme Precursors | 2 | 2000 | 20 | 0.080 |
Why?
|
| Mortality | 1 | 2011 | 158 | 0.080 |
Why?
|
| Infusions, Intravenous | 7 | 2001 | 402 | 0.080 |
Why?
|
| Culture Media, Conditioned | 2 | 2002 | 102 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2004 | 87 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 83 | 0.080 |
Why?
|
| Melphalan | 2 | 2023 | 98 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2010 | 229 | 0.080 |
Why?
|
| Clodronic Acid | 1 | 2010 | 9 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2000 | 47 | 0.080 |
Why?
|
| Rats, Inbred Strains | 2 | 2006 | 300 | 0.080 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 289 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2014 | 381 | 0.080 |
Why?
|
| Cytosol | 4 | 2015 | 193 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 258 | 0.080 |
Why?
|
| Exons | 1 | 1991 | 451 | 0.080 |
Why?
|
| Actuarial Analysis | 8 | 2001 | 60 | 0.080 |
Why?
|
| Calcium | 2 | 1994 | 1196 | 0.080 |
Why?
|
| Nucleotides | 2 | 2012 | 93 | 0.080 |
Why?
|
| Simvastatin | 1 | 2010 | 106 | 0.080 |
Why?
|
| Tissue Extracts | 1 | 2009 | 24 | 0.080 |
Why?
|
| Receptors, CCR2 | 2 | 2021 | 34 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2007 | 80 | 0.080 |
Why?
|
| Protein Kinase C-delta | 6 | 2000 | 29 | 0.080 |
Why?
|
| Ethylenediamines | 2 | 1999 | 14 | 0.080 |
Why?
|
| Gels | 1 | 2009 | 53 | 0.070 |
Why?
|
| Mutagens | 3 | 2015 | 29 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2009 | 52 | 0.070 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2001 | 7 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2000 | 201 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 384 | 0.070 |
Why?
|
| Lead Radioisotopes | 1 | 1989 | 6 | 0.070 |
Why?
|
| Meiosis | 2 | 2001 | 87 | 0.070 |
Why?
|
| DNA Probes | 2 | 2020 | 66 | 0.070 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2008 | 4 | 0.070 |
Why?
|
| Hydrogen Peroxide | 4 | 2013 | 173 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2001 | 152 | 0.070 |
Why?
|
| Wnt1 Protein | 1 | 2008 | 27 | 0.070 |
Why?
|
| Suppression, Genetic | 1 | 2008 | 30 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2020 | 152 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 114 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 103 | 0.070 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 52 | 0.070 |
Why?
|
| Caspase 1 | 2 | 2021 | 22 | 0.070 |
Why?
|
| Ileum | 1 | 2009 | 172 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2009 | 126 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2009 | 84 | 0.070 |
Why?
|
| Ethanolamines | 2 | 2000 | 25 | 0.070 |
Why?
|
| Carotid Artery Injuries | 1 | 2008 | 22 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2783 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 539 | 0.070 |
Why?
|
| Oleic Acids | 2 | 2000 | 33 | 0.070 |
Why?
|
| Interleukins | 1 | 2009 | 135 | 0.070 |
Why?
|
| Endocannabinoids | 2 | 2000 | 28 | 0.070 |
Why?
|
| G1 Phase | 4 | 1999 | 66 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1988 | 157 | 0.070 |
Why?
|
| Neuroblastoma | 4 | 2020 | 409 | 0.070 |
Why?
|
| Socioeconomic Factors | 5 | 2017 | 661 | 0.070 |
Why?
|
| Etoposide | 2 | 2007 | 207 | 0.070 |
Why?
|
| Radiography | 5 | 2014 | 762 | 0.070 |
Why?
|
| Logistic Models | 3 | 2017 | 1273 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 202 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 556 | 0.070 |
Why?
|
| Hypoxia | 1 | 2013 | 681 | 0.070 |
Why?
|
| Small Molecule Libraries | 1 | 2008 | 73 | 0.070 |
Why?
|
| Algorithms | 4 | 2018 | 2001 | 0.070 |
Why?
|
| Drug Therapy, Combination | 15 | 1982 | 762 | 0.070 |
Why?
|
| Carcinogenesis | 2 | 2020 | 242 | 0.070 |
Why?
|
| Protein Biosynthesis | 3 | 2019 | 393 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2009 | 206 | 0.070 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 1992 | 36 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2007 | 51 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1989 | 195 | 0.070 |
Why?
|
| Tissue Engineering | 1 | 2009 | 203 | 0.070 |
Why?
|
| Acetylation | 1 | 2007 | 151 | 0.070 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 238 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 1998 | 306 | 0.060 |
Why?
|
| Muscle, Skeletal | 3 | 2011 | 521 | 0.060 |
Why?
|
| Protein Transport | 2 | 2016 | 448 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2018 | 137 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2009 | 315 | 0.060 |
Why?
|
| Cetuximab | 1 | 2007 | 119 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 166 | 0.060 |
Why?
|
| Imidazoles | 1 | 2007 | 141 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2000 | 667 | 0.060 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 91 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2005 | 212 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2013 | 1302 | 0.060 |
Why?
|
| Loss of Heterozygosity | 3 | 2017 | 84 | 0.060 |
Why?
|
| Cricetulus | 6 | 1987 | 123 | 0.060 |
Why?
|
| Chlorophyll | 2 | 2016 | 45 | 0.060 |
Why?
|
| Oxidoreductases | 2 | 2005 | 112 | 0.060 |
Why?
|
| Drug Compounding | 2 | 2019 | 97 | 0.060 |
Why?
|
| Serine | 2 | 2020 | 106 | 0.060 |
Why?
|
| Diploidy | 4 | 1983 | 36 | 0.060 |
Why?
|
| Sirtuins | 1 | 2007 | 79 | 0.060 |
Why?
|
| Genes, BRCA1 | 2 | 2014 | 191 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 5 | 2000 | 98 | 0.060 |
Why?
|
| Models, Animal | 3 | 2003 | 279 | 0.060 |
Why?
|
| Palladium | 1 | 2006 | 5 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2012 | 2666 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 1989 | 849 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 2008 | 0.060 |
Why?
|
| Computational Biology | 1 | 2010 | 614 | 0.060 |
Why?
|
| Cattle | 2 | 2000 | 397 | 0.060 |
Why?
|
| Blotting, Northern | 4 | 1994 | 239 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2005 | 7 | 0.060 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 14 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 4 | 1999 | 41 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2009 | 850 | 0.060 |
Why?
|
| Cell Line, Transformed | 3 | 2002 | 153 | 0.060 |
Why?
|
| Genes, ras | 1 | 2006 | 97 | 0.060 |
Why?
|
| Benz(a)Anthracenes | 2 | 1983 | 4 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 1983 | 8 | 0.060 |
Why?
|
| Cytoplasm | 5 | 2009 | 276 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2017 | 84 | 0.060 |
Why?
|
| SEER Program | 2 | 2020 | 243 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2014 | 255 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2017 | 374 | 0.060 |
Why?
|
| Flavonoids | 1 | 2006 | 86 | 0.060 |
Why?
|
| Endothelium | 1 | 2005 | 63 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 2 | 2021 | 146 | 0.060 |
Why?
|
| Langerhans Cells | 2 | 1983 | 17 | 0.060 |
Why?
|
| NAD+ Nucleosidase | 1 | 1985 | 2 | 0.060 |
Why?
|
| Retreatment | 2 | 2017 | 106 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2026 | 181 | 0.060 |
Why?
|
| Monocytes | 4 | 1993 | 219 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2002 | 48 | 0.060 |
Why?
|
| Random Allocation | 4 | 2003 | 311 | 0.060 |
Why?
|
| Cesium Radioisotopes | 6 | 1998 | 12 | 0.050 |
Why?
|
| Chicago | 4 | 2014 | 1513 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 5 | 1999 | 195 | 0.050 |
Why?
|
| Mouth Mucosa | 2 | 1983 | 71 | 0.050 |
Why?
|
| Exodeoxyribonucleases | 2 | 2001 | 15 | 0.050 |
Why?
|
| Cortisone | 2 | 1981 | 9 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2016 | 72 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 75 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 356 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1988 | 479 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 96 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2002 | 85 | 0.050 |
Why?
|
| Lipids | 2 | 2016 | 293 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 139 | 0.050 |
Why?
|
| Ovary | 5 | 1987 | 260 | 0.050 |
Why?
|
| Azacitidine | 2 | 2018 | 152 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 834 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2023 | 498 | 0.050 |
Why?
|
| Veins | 1 | 2005 | 87 | 0.050 |
Why?
|
| U937 Cells | 5 | 2005 | 32 | 0.050 |
Why?
|
| Isocoumarins | 2 | 2001 | 7 | 0.050 |
Why?
|
| Phospholipases A2 | 2 | 1994 | 45 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 94 | 0.050 |
Why?
|
| Xeroderma Pigmentosum | 4 | 1984 | 9 | 0.050 |
Why?
|
| Decision Making | 5 | 2020 | 685 | 0.050 |
Why?
|
| Incidence | 3 | 1997 | 1776 | 0.050 |
Why?
|
| 3T3 Cells | 4 | 1996 | 94 | 0.050 |
Why?
|
| Phospholipases A | 2 | 1994 | 46 | 0.050 |
Why?
|
| bcl-X Protein | 4 | 2000 | 57 | 0.050 |
Why?
|
| Eyelid Neoplasms | 1 | 1984 | 7 | 0.050 |
Why?
|
| Collagen Type XVIII | 2 | 2000 | 4 | 0.050 |
Why?
|
| Cytosine Deaminase | 3 | 2000 | 6 | 0.050 |
Why?
|
| Endostatins | 2 | 2000 | 6 | 0.050 |
Why?
|
| Cholesterol Oxidase | 1 | 2023 | 12 | 0.050 |
Why?
|
| Scandium | 1 | 2023 | 4 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 269 | 0.050 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Pyroptosis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Molecular Biology | 2 | 1996 | 83 | 0.050 |
Why?
|
| Antibodies | 2 | 2016 | 349 | 0.050 |
Why?
|
| Infant | 10 | 2016 | 3329 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2003 | 15 | 0.050 |
Why?
|
| Ultraviolet Rays | 8 | 1996 | 198 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2003 | 31 | 0.050 |
Why?
|
| Autocrine Communication | 1 | 2003 | 20 | 0.050 |
Why?
|
| Epidermal Growth Factor | 2 | 1995 | 116 | 0.050 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2003 | 22 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2003 | 20 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2015 | 99 | 0.050 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 51 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 35 | 0.050 |
Why?
|
| Cyclins | 4 | 2001 | 80 | 0.050 |
Why?
|
| Tyrosine | 4 | 1997 | 135 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2002 | 51 | 0.050 |
Why?
|
| Vidarabine | 1 | 2023 | 107 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2003 | 43 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2004 | 261 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 55 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 86 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2002 | 159 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2003 | 119 | 0.050 |
Why?
|
| Plasminogen Activators | 1 | 2002 | 10 | 0.040 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 13 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 49 | 0.040 |
Why?
|
| Guanidines | 1 | 2002 | 34 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 87 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2013 | 136 | 0.040 |
Why?
|
| Collagenases | 1 | 2022 | 42 | 0.040 |
Why?
|
| DNA Primers | 2 | 2015 | 530 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2023 | 111 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 159 | 0.040 |
Why?
|
| Muscle Neoplasms | 1 | 2002 | 16 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2001 | 22 | 0.040 |
Why?
|
| Basement Membrane | 2 | 2000 | 58 | 0.040 |
Why?
|
| Bone Marrow | 3 | 1992 | 418 | 0.040 |
Why?
|
| Phenols | 1 | 2002 | 51 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 62 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2001 | 58 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 370 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 146 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2001 | 76 | 0.040 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2001 | 28 | 0.040 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2001 | 24 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 27 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2021 | 68 | 0.040 |
Why?
|
| Immune System | 1 | 2022 | 106 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2001 | 92 | 0.040 |
Why?
|
| Linear Models | 1 | 2002 | 424 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 309 | 0.040 |
Why?
|
| Connexin 43 | 1 | 2001 | 95 | 0.040 |
Why?
|
| X-Ray Film | 1 | 2020 | 37 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2002 | 207 | 0.040 |
Why?
|
| Stomatitis | 2 | 1992 | 30 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1384 | 0.040 |
Why?
|
| Polyesters | 1 | 2020 | 44 | 0.040 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 6 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 63 | 0.040 |
Why?
|
| Escherichia coli | 2 | 2000 | 572 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2001 | 156 | 0.040 |
Why?
|
| Serpins | 2 | 1999 | 31 | 0.040 |
Why?
|
| Arteries | 2 | 2007 | 170 | 0.040 |
Why?
|
| Hydrogels | 1 | 2021 | 94 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pichia | 1 | 2000 | 33 | 0.040 |
Why?
|
| Butyric Acid | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Migration Inhibition | 1 | 2000 | 8 | 0.040 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2020 | 16 | 0.040 |
Why?
|
| Fanconi Anemia | 2 | 1984 | 10 | 0.040 |
Why?
|
| RNA Caps | 1 | 2000 | 7 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2020 | 80 | 0.040 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 4 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2000 | 45 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 63 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 1980 | 27 | 0.040 |
Why?
|
| Microcirculation | 1 | 2000 | 101 | 0.040 |
Why?
|
| Cell Separation | 1 | 2000 | 200 | 0.040 |
Why?
|
| Cyclin B | 1 | 2000 | 16 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 59 | 0.040 |
Why?
|
| Choroid Neoplasms | 1 | 1980 | 5 | 0.040 |
Why?
|
| Cyclin A | 1 | 2000 | 27 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2001 | 163 | 0.040 |
Why?
|
| Replication Protein A | 2 | 2015 | 16 | 0.040 |
Why?
|
| Permeability | 1 | 2000 | 145 | 0.040 |
Why?
|
| Functional Laterality | 2 | 2017 | 199 | 0.040 |
Why?
|
| Uveal Diseases | 1 | 1979 | 2 | 0.040 |
Why?
|
| Protein Interaction Mapping | 2 | 2010 | 79 | 0.040 |
Why?
|
| Body Weight | 2 | 2000 | 455 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 171 | 0.040 |
Why?
|
| Hormones | 1 | 1980 | 138 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Resistance | 5 | 1995 | 233 | 0.040 |
Why?
|
| Sphingomyelins | 2 | 1996 | 15 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1980 | 215 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1979 | 35 | 0.040 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1999 | 33 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 103 | 0.040 |
Why?
|
| Naphthalenes | 2 | 1996 | 43 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2000 | 403 | 0.040 |
Why?
|
| Precipitin Tests | 4 | 2002 | 101 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2000 | 799 | 0.040 |
Why?
|
| Immunization | 2 | 2012 | 154 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1980 | 104 | 0.040 |
Why?
|
| Biopsy | 2 | 2018 | 1224 | 0.040 |
Why?
|
| Artemisinins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 185 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 109 | 0.040 |
Why?
|
| Lysine | 1 | 2020 | 181 | 0.040 |
Why?
|
| Age Factors | 4 | 2014 | 1960 | 0.040 |
Why?
|
| Cathepsins | 1 | 2019 | 22 | 0.040 |
Why?
|
| Erythrocyte Membrane | 1 | 1999 | 61 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Tonsillar Neoplasms | 2 | 1997 | 6 | 0.040 |
Why?
|
| Methylnitronitrosoguanidine | 3 | 1989 | 16 | 0.040 |
Why?
|
| Anemia, Aplastic | 1 | 1979 | 34 | 0.040 |
Why?
|
| Aorta | 1 | 2000 | 275 | 0.040 |
Why?
|
| Brain | 3 | 2014 | 2429 | 0.040 |
Why?
|
| Gene Targeting | 1 | 1999 | 72 | 0.040 |
Why?
|
| Growth Substances | 2 | 1993 | 79 | 0.040 |
Why?
|
| Infant, Newborn | 6 | 2008 | 2529 | 0.040 |
Why?
|
| Neck | 1 | 1999 | 103 | 0.040 |
Why?
|
| Endosomes | 1 | 2019 | 91 | 0.040 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.040 |
Why?
|
| Head | 1 | 1999 | 135 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2000 | 104 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 62 | 0.030 |
Why?
|
| Retroviridae | 2 | 1997 | 74 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2000 | 126 | 0.030 |
Why?
|
| Hydroxyl Radical | 1 | 2018 | 38 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 658 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1992 | 262 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 310 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 2005 | 102 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2008 | 67 | 0.030 |
Why?
|
| Laser Therapy | 2 | 1990 | 149 | 0.030 |
Why?
|
| Caspase 9 | 3 | 2005 | 47 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 387 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 492 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 61 | 0.030 |
Why?
|
| Mastectomy | 2 | 1997 | 271 | 0.030 |
Why?
|
| Glossectomy | 1 | 2017 | 4 | 0.030 |
Why?
|
| Endemic Diseases | 1 | 1997 | 7 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 175 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2017 | 20 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 187 | 0.030 |
Why?
|
| Insurance, Health | 2 | 2015 | 186 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2017 | 23 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 103 | 0.030 |
Why?
|
| Ceramidases | 1 | 1997 | 4 | 0.030 |
Why?
|
| Staurosporine | 2 | 2000 | 34 | 0.030 |
Why?
|
| Oral Surgical Procedures | 1 | 2017 | 19 | 0.030 |
Why?
|
| Herpesviridae | 1 | 1997 | 13 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2001 | 566 | 0.030 |
Why?
|
| Amidohydrolases | 1 | 1997 | 17 | 0.030 |
Why?
|
| Intravital Microscopy | 1 | 2017 | 15 | 0.030 |
Why?
|
| Thymidylate Synthase | 1 | 1997 | 15 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 1997 | 29 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1997 | 114 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2017 | 33 | 0.030 |
Why?
|
| Cell Lineage | 1 | 1998 | 332 | 0.030 |
Why?
|
| Penile Erection | 1 | 1997 | 22 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2000 | 285 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 194 | 0.030 |
Why?
|
| Cytotoxins | 2 | 2009 | 18 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 1977 | 25 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 87 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2017 | 54 | 0.030 |
Why?
|
| Contrast Media | 2 | 2018 | 1011 | 0.030 |
Why?
|
| Nucleosomes | 2 | 1995 | 63 | 0.030 |
Why?
|
| Singlet Oxygen | 1 | 2016 | 7 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 102 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 99 | 0.030 |
Why?
|
| Transgenes | 1 | 1997 | 173 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 135 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 467 | 0.030 |
Why?
|
| Pyramidal Cells | 1 | 1997 | 84 | 0.030 |
Why?
|
| Gliosarcoma | 1 | 1996 | 10 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1996 | 47 | 0.030 |
Why?
|
| Proton Therapy | 1 | 2016 | 44 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 81 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1996 | 19 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 395 | 0.030 |
Why?
|
| Software | 1 | 2000 | 693 | 0.030 |
Why?
|
| Urography | 1 | 1996 | 30 | 0.030 |
Why?
|
| RNA, Small Untranslated | 1 | 2016 | 18 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 174 | 0.030 |
Why?
|
| Zinc Sulfate | 1 | 1995 | 1 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 155 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 290 | 0.030 |
Why?
|
| Technology, Radiologic | 1 | 2016 | 105 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 330 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2016 | 75 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2015 | 14 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2005 | 411 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 85 | 0.030 |
Why?
|
| Sulfates | 1 | 1995 | 38 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 98 | 0.030 |
Why?
|
| Radiation | 1 | 2015 | 16 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2016 | 68 | 0.030 |
Why?
|
| Cats | 1 | 1996 | 281 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1995 | 18 | 0.030 |
Why?
|
| Acetylglucosamine | 1 | 2015 | 18 | 0.030 |
Why?
|
| Mastadenovirus | 1 | 1995 | 3 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 1997 | 151 | 0.030 |
Why?
|
| Leukocytes | 1 | 1996 | 212 | 0.030 |
Why?
|
| Private Sector | 1 | 2015 | 23 | 0.030 |
Why?
|
| Bone Resorption | 2 | 1988 | 42 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 70 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 1995 | 71 | 0.030 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1997 | 147 | 0.030 |
Why?
|
| Vitamin A | 1 | 1995 | 29 | 0.030 |
Why?
|
| Mammography | 2 | 2010 | 504 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 3 | 2001 | 43 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 13 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 548 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 10c | 1 | 2015 | 3 | 0.030 |
Why?
|
| Bone and Bones | 2 | 2014 | 270 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 64 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 1993 | 66 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 291 | 0.030 |
Why?
|
| Carotid Artery, Common | 2 | 2008 | 28 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 14 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1975 | 16 | 0.030 |
Why?
|
| Drug Interactions | 2 | 1990 | 239 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2015 | 57 | 0.030 |
Why?
|
| Comet Assay | 1 | 2015 | 8 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 446 | 0.030 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 10 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 237 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 345 | 0.030 |
Why?
|
| Hemoglobins | 2 | 1999 | 198 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 74 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1992 | 107 | 0.030 |
Why?
|
| Gliosis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Surgical Flaps | 2 | 1995 | 252 | 0.030 |
Why?
|
| Filgrastim | 1 | 1994 | 56 | 0.030 |
Why?
|
| Kyphosis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1993 | 66 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 1996 | 152 | 0.030 |
Why?
|
| Vinblastine | 2 | 1993 | 84 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2014 | 38 | 0.030 |
Why?
|
| Busulfan | 1 | 2014 | 41 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1994 | 7 | 0.030 |
Why?
|
| Community Health Services | 1 | 2015 | 81 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1994 | 38 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 1994 | 32 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1994 | 65 | 0.030 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1994 | 15 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 1994 | 63 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1994 | 36 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 106 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1995 | 118 | 0.030 |
Why?
|
| Cause of Death | 1 | 1995 | 278 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 64 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 1994 | 37 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 2555 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 55 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 1995 | 127 | 0.030 |
Why?
|
| Chelating Agents | 1 | 1994 | 68 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 731 | 0.030 |
Why?
|
| Dicumarol | 1 | 1993 | 1 | 0.030 |
Why?
|
| Muscles | 1 | 1994 | 179 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 301 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 10 | 0.020 |
Why?
|
| Convection | 1 | 2013 | 11 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 23 | 0.020 |
Why?
|
| Thrombosis | 1 | 1996 | 318 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 1997 | 301 | 0.020 |
Why?
|
| Brain Mapping | 1 | 1997 | 570 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1995 | 312 | 0.020 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 13 | 0.020 |
Why?
|
| Pneumonia | 2 | 2013 | 195 | 0.020 |
Why?
|
| Allografts | 1 | 2014 | 220 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2013 | 30 | 0.020 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 162 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 141 | 0.020 |
Why?
|
| Laparotomy | 2 | 2006 | 64 | 0.020 |
Why?
|
| Hippocampus | 1 | 1997 | 462 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 1994 | 126 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1996 | 720 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 201 | 0.020 |
Why?
|
| Methods | 3 | 1989 | 134 | 0.020 |
Why?
|
| Jugular Veins | 2 | 2005 | 65 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2013 | 41 | 0.020 |
Why?
|
| Taxoids | 1 | 2013 | 127 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 390 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 142 | 0.020 |
Why?
|
| Oxidation-Reduction | 3 | 2002 | 419 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1567 | 0.020 |
Why?
|
| Plants, Toxic | 1 | 1992 | 23 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 407 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 820 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 187 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2013 | 133 | 0.020 |
Why?
|
| Smoking | 2 | 1997 | 674 | 0.020 |
Why?
|
| Phosphorus | 1 | 1992 | 119 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 630 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 31 | 0.020 |
Why?
|
| Pyrimidine Nucleosides | 1 | 1992 | 5 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 2002 | 116 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1992 | 35 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 39 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2011 | 46 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.020 |
Why?
|
| Everolimus | 1 | 2012 | 35 | 0.020 |
Why?
|
| Thorax | 1 | 2012 | 77 | 0.020 |
Why?
|
| Micronucleus Tests | 1 | 2011 | 5 | 0.020 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2011 | 3 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2003 | 23 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 721 | 0.020 |
Why?
|
| Menopause | 1 | 1992 | 94 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1991 | 91 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 1991 | 112 | 0.020 |
Why?
|
| ROC Curve | 2 | 2004 | 793 | 0.020 |
Why?
|
| Free Radicals | 1 | 1991 | 72 | 0.020 |
Why?
|
| Chromatography, Paper | 1 | 1991 | 11 | 0.020 |
Why?
|
| Biotransformation | 1 | 1991 | 46 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2008 | 745 | 0.020 |
Why?
|
| Astatine | 1 | 1990 | 3 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 1992 | 207 | 0.020 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 1990 | 15 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1990 | 42 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 1990 | 52 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 144 | 0.020 |
Why?
|
| Culture Media | 3 | 2004 | 138 | 0.020 |
Why?
|
| Glomus Jugulare Tumor | 1 | 1990 | 2 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 358 | 0.020 |
Why?
|
| Chromatin | 1 | 2014 | 454 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 2 | 2000 | 8 | 0.020 |
Why?
|
| Radiation Genetics | 2 | 1993 | 7 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1990 | 50 | 0.020 |
Why?
|
| Cell-Free System | 2 | 2000 | 45 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2010 | 27 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 41 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 1990 | 20 | 0.020 |
Why?
|
| Niacinamide | 2 | 1993 | 105 | 0.020 |
Why?
|
| Disclosure | 1 | 1991 | 98 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2004 | 77 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2000 | 238 | 0.020 |
Why?
|
| Vulva | 1 | 1990 | 25 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1990 | 19 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 80 | 0.020 |
Why?
|
| Sarcoma, Ewing | 2 | 1988 | 42 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 419 | 0.020 |
Why?
|
| Chromosome Disorders | 4 | 1986 | 97 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 26 | 0.020 |
Why?
|
| COS Cells | 2 | 2000 | 163 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1990 | 175 | 0.020 |
Why?
|
| Esthetics | 1 | 1989 | 52 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 280 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2009 | 84 | 0.020 |
Why?
|
| CREB-Binding Protein | 2 | 1999 | 16 | 0.020 |
Why?
|
| Urogenital System | 1 | 2009 | 11 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 95 | 0.020 |
Why?
|
| Theophylline | 2 | 1993 | 34 | 0.020 |
Why?
|
| Tumor Protein p73 | 2 | 1999 | 6 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2001 | 25 | 0.020 |
Why?
|
| Chromosome Mapping | 4 | 1988 | 1061 | 0.020 |
Why?
|
| History, 19th Century | 1 | 1989 | 57 | 0.020 |
Why?
|
| Mediastinum | 1 | 1989 | 42 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 108 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2001 | 76 | 0.020 |
Why?
|
| Facial Bones | 1 | 1989 | 36 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 90 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 244 | 0.020 |
Why?
|
| Dactinomycin | 4 | 1992 | 32 | 0.020 |
Why?
|
| Shear Strength | 1 | 2008 | 17 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1989 | 117 | 0.020 |
Why?
|
| Cystadenocarcinoma | 1 | 1988 | 12 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 1989 | 38 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 301 | 0.020 |
Why?
|
| Syndrome | 2 | 1980 | 438 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2008 | 48 | 0.020 |
Why?
|
| Methyl Methanesulfonate | 2 | 2000 | 4 | 0.020 |
Why?
|
| Hysterectomy | 1 | 1990 | 174 | 0.020 |
Why?
|
| Chromosomes | 2 | 1998 | 91 | 0.020 |
Why?
|
| Virulence | 1 | 2009 | 280 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 122 | 0.020 |
Why?
|
| Nose | 1 | 1989 | 97 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 197 | 0.020 |
Why?
|
| Mandibular Prosthesis | 1 | 1988 | 1 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1988 | 14 | 0.020 |
Why?
|
| Lymphoma | 2 | 1981 | 254 | 0.020 |
Why?
|
| src Homology Domains | 2 | 1999 | 46 | 0.020 |
Why?
|
| Proteome | 1 | 2009 | 163 | 0.020 |
Why?
|
| Leukemia, Promyelocytic, Acute | 3 | 1993 | 48 | 0.020 |
Why?
|
| Mesocricetus | 3 | 1983 | 103 | 0.020 |
Why?
|
| Outpatients | 1 | 1989 | 106 | 0.020 |
Why?
|
| Bone Plates | 1 | 1988 | 33 | 0.020 |
Why?
|
| Trisomy | 3 | 1983 | 53 | 0.020 |
Why?
|
| Abnormalities, Multiple | 2 | 1979 | 235 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2006 | 968 | 0.020 |
Why?
|
| Hydrolysis | 2 | 1999 | 145 | 0.020 |
Why?
|
| Fluoresceins | 2 | 2000 | 43 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1989 | 323 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 282 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 251 | 0.020 |
Why?
|
| HL-60 Cells | 2 | 1998 | 26 | 0.020 |
Why?
|
| Methyltransferases | 1 | 1989 | 218 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 488 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1989 | 201 | 0.020 |
Why?
|
| Cycloheximide | 3 | 1991 | 54 | 0.020 |
Why?
|
| Phosphotyrosine | 2 | 1998 | 31 | 0.020 |
Why?
|
| Calcitriol | 1 | 1988 | 173 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 125 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 194 | 0.020 |
Why?
|
| Testicular Neoplasms | 2 | 1979 | 126 | 0.020 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1986 | 5 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 600 | 0.020 |
Why?
|
| Iris | 1 | 1986 | 4 | 0.020 |
Why?
|
| Axilla | 2 | 1997 | 109 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 472 | 0.010 |
Why?
|
| Phorbols | 1 | 1985 | 5 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2006 | 71 | 0.010 |
Why?
|
| Granulocytes | 1 | 1986 | 34 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 443 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 1005 | 0.010 |
Why?
|
| Prednisone | 2 | 1992 | 251 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 10 | 0.010 |
Why?
|
| Homozygote | 1 | 1986 | 212 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 2 | 1983 | 116 | 0.010 |
Why?
|
| Laryngectomy | 2 | 1984 | 26 | 0.010 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.010 |
Why?
|
| Inpatients | 1 | 1989 | 367 | 0.010 |
Why?
|
| GATA6 Transcription Factor | 1 | 2005 | 13 | 0.010 |
Why?
|
| meta-Aminobenzoates | 1 | 1985 | 1 | 0.010 |
Why?
|
| Hypoxanthines | 1 | 1985 | 11 | 0.010 |
Why?
|
| Hypoxanthine | 1 | 1985 | 4 | 0.010 |
Why?
|
| CHO Cells | 2 | 1998 | 188 | 0.010 |
Why?
|
| Aminobenzoates | 1 | 1985 | 7 | 0.010 |
Why?
|
| Thymidine | 1 | 1985 | 58 | 0.010 |
Why?
|
| Cell Transformation, Viral | 2 | 1986 | 38 | 0.010 |
Why?
|
| Estrogen Antagonists | 2 | 1984 | 47 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 832 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 1994 | 34 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 128 | 0.010 |
Why?
|
| Dextrans | 1 | 2004 | 77 | 0.010 |
Why?
|
| NAD | 1 | 1985 | 102 | 0.010 |
Why?
|
| Parotid Neoplasms | 1 | 1984 | 22 | 0.010 |
Why?
|
| Integrin alphaV | 1 | 2004 | 4 | 0.010 |
Why?
|
| Bacteriophage M13 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2004 | 16 | 0.010 |
Why?
|
| Multigene Family | 1 | 2005 | 204 | 0.010 |
Why?
|
| Remission, Spontaneous | 3 | 1978 | 45 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 2004 | 36 | 0.010 |
Why?
|
| Hypothyroidism | 2 | 1985 | 299 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 2 | 2001 | 141 | 0.010 |
Why?
|
| Glottis | 1 | 1984 | 13 | 0.010 |
Why?
|
| Peptide Library | 1 | 2004 | 87 | 0.010 |
Why?
|
| Host Cell Factor C1 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Nocodazole | 1 | 2003 | 18 | 0.010 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2003 | 20 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1983 | 18 | 0.010 |
Why?
|
| Hematopoiesis | 2 | 1986 | 186 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1983 | 14 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1991 | 802 | 0.010 |
Why?
|
| Umbilical Arteries | 1 | 2003 | 13 | 0.010 |
Why?
|
| Stereoisomerism | 2 | 1996 | 102 | 0.010 |
Why?
|
| Mesothelioma | 2 | 1989 | 346 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2006 | 398 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1983 | 77 | 0.010 |
Why?
|
| Thymidine Kinase | 2 | 1993 | 30 | 0.010 |
Why?
|
| Chromosome Inversion | 1 | 1983 | 45 | 0.010 |
Why?
|
| Diaphragm | 1 | 1983 | 76 | 0.010 |
Why?
|
| Hospitalization | 1 | 1989 | 982 | 0.010 |
Why?
|
| Chickens | 2 | 1993 | 195 | 0.010 |
Why?
|
| Misonidazole | 1 | 1982 | 19 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2002 | 38 | 0.010 |
Why?
|
| Gardner Syndrome | 1 | 1982 | 1 | 0.010 |
Why?
|
| Genes, myb | 1 | 2002 | 5 | 0.010 |
Why?
|
| Genes, fos | 2 | 1992 | 24 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2002 | 38 | 0.010 |
Why?
|
| Biological Assay | 1 | 1982 | 82 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1991 | 3021 | 0.010 |
Why?
|
| Genes, myc | 1 | 2002 | 38 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2002 | 38 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 95 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 150 | 0.010 |
Why?
|
| Cocarcinogenesis | 1 | 1981 | 11 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2002 | 285 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2002 | 178 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2001 | 61 | 0.010 |
Why?
|
| Leupeptins | 1 | 2001 | 21 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1982 | 85 | 0.010 |
Why?
|
| Exodeoxyribonuclease V | 1 | 2001 | 4 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 3 | 1987 | 76 | 0.010 |
Why?
|
| Staining and Labeling | 2 | 1998 | 161 | 0.010 |
Why?
|
| Pedigree | 2 | 1984 | 980 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2001 | 120 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1982 | 64 | 0.010 |
Why?
|
| Rec A Recombinases | 1 | 2001 | 14 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1981 | 48 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2001 | 25 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 2001 | 44 | 0.010 |
Why?
|
| Neurofibroma | 1 | 1981 | 12 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1981 | 28 | 0.010 |
Why?
|
| DNA Repair Enzymes | 1 | 2001 | 63 | 0.010 |
Why?
|
| Purines | 1 | 2001 | 96 | 0.010 |
Why?
|
| Speech | 1 | 1981 | 91 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 709 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2001 | 85 | 0.010 |
Why?
|
| Fibroma | 1 | 1981 | 30 | 0.010 |
Why?
|
| Osteoma | 1 | 1980 | 4 | 0.010 |
Why?
|
| E2F5 Transcription Factor | 1 | 2000 | 2 | 0.010 |
Why?
|
| E2F4 Transcription Factor | 1 | 2000 | 2 | 0.010 |
Why?
|
| Friend murine leukemia virus | 1 | 1980 | 5 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 2000 | 5 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 2000 | 10 | 0.010 |
Why?
|
| E2F2 Transcription Factor | 1 | 2000 | 5 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 483 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2000 | 16 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2000 | 2 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2000 | 21 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2000 | 64 | 0.010 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2000 | 10 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 2001 | 148 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 73 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 1980 | 28 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2000 | 136 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 68 | 0.010 |
Why?
|
| Arrestin | 1 | 2000 | 5 | 0.010 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2000 | 16 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2000 | 129 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2000 | 18 | 0.010 |
Why?
|
| Progeria | 1 | 1980 | 5 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2000 | 89 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1984 | 831 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1980 | 20 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2000 | 37 | 0.010 |
Why?
|
| Peptide Initiation Factors | 1 | 2000 | 30 | 0.010 |
Why?
|
| Paget Disease, Extramammary | 1 | 1980 | 8 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 220 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1979 | 10 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 69 | 0.010 |
Why?
|
| Procarbazine | 1 | 1979 | 27 | 0.010 |
Why?
|
| Photosensitivity Disorders | 1 | 1979 | 14 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 1999 | 46 | 0.010 |
Why?
|
| Avian Proteins | 1 | 1999 | 18 | 0.010 |
Why?
|
| Genes, Essential | 1 | 1999 | 19 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2000 | 138 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 84 | 0.010 |
Why?
|
| Vitamin K | 1 | 1999 | 27 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1979 | 16 | 0.010 |
Why?
|
| Dysgerminoma | 1 | 1979 | 7 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1980 | 183 | 0.010 |
Why?
|
| Protons | 1 | 1980 | 102 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 303 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1979 | 69 | 0.010 |
Why?
|
| Illinois | 1 | 2001 | 522 | 0.010 |
Why?
|
| Optic Nerve | 1 | 1979 | 35 | 0.010 |
Why?
|
| Eye Abnormalities | 1 | 1979 | 41 | 0.010 |
Why?
|
| Research Design | 1 | 2003 | 650 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 52 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 2000 | 177 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 68 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 273 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 401 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 209 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 257 | 0.010 |
Why?
|
| Levoleucovorin | 1 | 1998 | 2 | 0.010 |
Why?
|
| Video Recording | 1 | 2000 | 214 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1944 | 0.010 |
Why?
|
| RNA, Catalytic | 1 | 1999 | 137 | 0.010 |
Why?
|
| Wound Infection | 1 | 1978 | 17 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2000 | 220 | 0.010 |
Why?
|
| Spermatocytes | 1 | 1998 | 7 | 0.010 |
Why?
|
| Placenta | 1 | 2000 | 202 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1998 | 162 | 0.010 |
Why?
|
| Edema | 1 | 1978 | 68 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 1998 | 41 | 0.010 |
Why?
|
| Fistula | 1 | 1978 | 44 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1999 | 242 | 0.010 |
Why?
|
| Microvilli | 1 | 1977 | 44 | 0.010 |
Why?
|
| Ku Autoantigen | 1 | 1997 | 15 | 0.010 |
Why?
|
| Retina | 1 | 1979 | 221 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 1997 | 28 | 0.010 |
Why?
|
| Patient Compliance | 2 | 1989 | 245 | 0.010 |
Why?
|
| Preoperative Care | 2 | 1990 | 418 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 1976 | 10 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1996 | 68 | 0.010 |
Why?
|
| Scapula | 1 | 1976 | 25 | 0.010 |
Why?
|
| Patient Participation | 1 | 1979 | 246 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 1996 | 41 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1996 | 10 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1996 | 94 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1996 | 16 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 15 | 0.010 |
Why?
|
| Tibia | 1 | 1976 | 85 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1996 | 161 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 1997 | 81 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1995 | 10 | 0.010 |
Why?
|
| Anisomycin | 1 | 1995 | 9 | 0.010 |
Why?
|
| Mitogens | 1 | 1995 | 58 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1995 | 51 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 66 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 1995 | 10 | 0.010 |
Why?
|
| Ear, External | 1 | 1975 | 24 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 1996 | 110 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1994 | 9 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1995 | 258 | 0.010 |
Why?
|
| Poloxalene | 1 | 1994 | 8 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1994 | 59 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1975 | 193 | 0.010 |
Why?
|
| Patients | 2 | 1989 | 104 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 164 | 0.010 |
Why?
|
| Globins | 1 | 1993 | 30 | 0.010 |
Why?
|
| Gene Conversion | 1 | 1992 | 23 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 13 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 119 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 1977 | 289 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 1992 | 46 | 0.010 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 9 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1992 | 13 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1992 | 20 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1992 | 34 | 0.010 |
Why?
|
| Triacetoneamine-N-Oxyl | 1 | 1991 | 3 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1983 | 435 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1993 | 176 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1992 | 271 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1991 | 59 | 0.010 |
Why?
|
| Alleles | 2 | 1986 | 1160 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 2 | 1984 | 19 | 0.010 |
Why?
|
| Perfusion | 1 | 1992 | 271 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1992 | 471 | 0.010 |
Why?
|
| Beta Particles | 1 | 1990 | 4 | 0.010 |
Why?
|
| Alpha Particles | 1 | 1990 | 4 | 0.010 |
Why?
|
| Vindesine | 1 | 1989 | 5 | 0.000 |
Why?
|
| Attitude | 2 | 1981 | 133 | 0.000 |
Why?
|
| RNA, Antisense | 1 | 1989 | 15 | 0.000 |
Why?
|
| Models, Structural | 1 | 1989 | 51 | 0.000 |
Why?
|
| Infusion Pumps | 1 | 1989 | 26 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 281 | 0.000 |
Why?
|
| Cytogenetics | 1 | 1988 | 27 | 0.000 |
Why?
|
| Tomography, Emission-Computed | 1 | 1989 | 103 | 0.000 |
Why?
|
| Epilepsies, Partial | 1 | 1989 | 52 | 0.000 |
Why?
|
| Stainless Steel | 1 | 1988 | 4 | 0.000 |
Why?
|
| Neurons | 1 | 1997 | 1619 | 0.000 |
Why?
|
| Patient Care Team | 2 | 1981 | 318 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1991 | 527 | 0.000 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1987 | 42 | 0.000 |
Why?
|
| Vasopressins | 1 | 1986 | 48 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 39 | 0.000 |
Why?
|
| Osteoradionecrosis | 1 | 1985 | 18 | 0.000 |
Why?
|
| Genes, Recessive | 1 | 1986 | 87 | 0.000 |
Why?
|
| Ulcer | 1 | 1985 | 38 | 0.000 |
Why?
|
| Retinal Detachment | 1 | 1986 | 61 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1985 | 82 | 0.000 |
Why?
|
| Ethyl Methanesulfonate | 1 | 1985 | 4 | 0.000 |
Why?
|
| Face | 1 | 1985 | 116 | 0.000 |
Why?
|
| Receptors, Estradiol | 1 | 1984 | 5 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1984 | 68 | 0.000 |
Why?
|
| Cheek | 1 | 1983 | 19 | 0.000 |
Why?
|
| Inguinal Canal | 1 | 1983 | 6 | 0.000 |
Why?
|
| Lymphography | 1 | 1983 | 25 | 0.000 |
Why?
|
| Thigh | 1 | 1983 | 42 | 0.000 |
Why?
|
| Antipyrine | 1 | 1983 | 4 | 0.000 |
Why?
|
| Idoxuridine | 1 | 1983 | 9 | 0.000 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1983 | 65 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1982 | 25 | 0.000 |
Why?
|
| Cell Count | 1 | 1983 | 195 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1982 | 94 | 0.000 |
Why?
|
| Boston | 1 | 1982 | 42 | 0.000 |
Why?
|
| Speech, Alaryngeal | 1 | 1981 | 3 | 0.000 |
Why?
|
| Occupations | 1 | 1981 | 25 | 0.000 |
Why?
|
| China | 1 | 1982 | 277 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1981 | 33 | 0.000 |
Why?
|
| Patient Care Planning | 1 | 1981 | 91 | 0.000 |
Why?
|
| Neutropenia | 1 | 1981 | 211 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1980 | 80 | 0.000 |
Why?
|
| Leukemia, Experimental | 1 | 1980 | 15 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1980 | 98 | 0.000 |
Why?
|
| Diffusion | 1 | 1980 | 95 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1980 | 166 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1981 | 226 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1981 | 194 | 0.000 |
Why?
|
| Palatal Neoplasms | 1 | 1979 | 3 | 0.000 |
Why?
|
| Telangiectasis | 1 | 1979 | 7 | 0.000 |
Why?
|
| Castration | 1 | 1979 | 32 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1979 | 139 | 0.000 |
Why?
|
| Myeloproliferative Disorders | 1 | 1981 | 154 | 0.000 |
Why?
|
| Caffeine | 1 | 1979 | 86 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1981 | 311 | 0.000 |
Why?
|
| Empyema | 1 | 1978 | 9 | 0.000 |
Why?
|
| Bronchial Fistula | 1 | 1978 | 10 | 0.000 |
Why?
|
| Hemoptysis | 1 | 1978 | 26 | 0.000 |
Why?
|
| Pleural Diseases | 1 | 1978 | 15 | 0.000 |
Why?
|
| Mathematics | 1 | 1977 | 176 | 0.000 |
Why?
|
| Attitude of Health Personnel | 1 | 1979 | 684 | 0.000 |
Why?
|
| Physicians | 1 | 1979 | 685 | 0.000 |
Why?
|